Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer
Caroline Mollévi(Inserm), Thierry Conroy(Inserm), Laurent Bedenne(CHU Dijon Bourgogne), Sophie Gourgou(Université de Montpellier), Pierre-Luc Etienne, Antoine Adenis(Inserm), Olivier Bouché(CHU Dijon Bourgogne), Béata Juzyna(UniCancer Group), Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), Marie‐Pierre Galais(Centre François Baclesse), Jean‐Yves Douillard(Integrated Oncology (United States))
Cited by 22
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k